leucovorin calcium / Generic mfg. 
Welcome,         Profile    Billing    Logout  
 424 Diseases   809 Trials   809 Trials   14393 News 


«12...103104105106107108109110111112113...235236»
  • ||||||||||  Keytruda (pembrolizumab) / Merck (MSD), Vitrakvi (larotrectinib) / Bayer
    Review, Journal, Tumor Mutational Burden, MSi-H Biomarker, PD(L)-1 Biomarker:  Treatment Approach to Adenocarcinoma of the Ampulla of Vater. (Pubmed Central) -  Feb 19, 2022   
    At a time when numerous therapeutic agents are in development, for example, those targeting specific K-RAS alterations or NRG fusions, identifying molecular aberrations can significantly impact patient outcomes as well as provide further insights into the biology of disease. In addition, based on recent data suggesting a significant prevalence of germline alterations in patients with ampullary tumors, referral to genetics counselors and germline testing is warranted in a significant proportion of patients with AC.
  • ||||||||||  Review, Journal, BRCA Biomarker, MSi-H Biomarker, PARP Biomarker, PD(L)-1 Biomarker, IO biomarker:  Systemic Therapy for Metastatic Pancreatic Cancer. (Pubmed Central) -  Feb 19, 2022   
    Options for first-line treatment are combination chemotherapy regimens such as FOLFIRINOX and gemcitabine plus nab-paclitaxel when the performance status of the patient is good...Recently, the PARP inhibitor olaparib has been demonstrated to improve progression-free survival when used as a maintenance treatment in the subgroup of patients with mPDAC and a BRCA1/-2 germ line mutation having received at least 16 weeks of platinum-based chemotherapy...Here, the combination of 5-FU/FA plus nanoliposomal irinotecan has shown to be superior to 5-FU/FA alone with respect to overall survival...Limited data in mPDACs shows that only a part of the already small subgroup of MSI-H mPDACs (frequency about 1%) appears to benefit substantially from a checkpoint inhibitor treatment. The identification of further subgroups, e.g., tumors with DNA damage repair deficiency, gene fusions, as well as novel approaches such as tumor-organoid-informed treatment decisions, may further improve therapeutic efficacy.
  • ||||||||||  5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg.
    Journal:  FOLFOX-HAIC active in large HCC. (Pubmed Central) -  Feb 19, 2022   
    The identification of further subgroups, e.g., tumors with DNA damage repair deficiency, gene fusions, as well as novel approaches such as tumor-organoid-informed treatment decisions, may further improve therapeutic efficacy. No abstract available
  • ||||||||||  Persistent Headaches and Ring-Enhancing Lesions in a Lung Transplant Recipient (Area J, Hall F (North Building, Exhibition Level), Moscone Center) -  Feb 19, 2022 - Abstract #ATS2022ATS_4484;    
    Definitive diagnosis of toxoplasmosis requires identification of tachyzoites in biopsy samples or clear seroconversion. In our case, ongoing symptoms of persistent headaches, brain imaging with ring-enhancing lesions, and toxoplasma mismatch prompted initiation of treatment with gradual improvement in symptoms.
  • ||||||||||  5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg.
    A Rare Case of Leriche Syndrome in a Patient with Colon Cancer: Case Report and Literature Review (Area G, Hall F (North Building, Exhibition Level), Moscone Center) -  Feb 19, 2022 - Abstract #ATS2022ATS_2881;    
    Retrospective data analysis shows that only 8.3% of patients with Aorto-iliac occlusion or stenosis had colorectal cancer. Our case highlights the association of this syndromic presentation in patients with colon cancer and is a reminder for clinicians to suspect its occurrence in case of leg pain or absent peripheral pulses.
  • ||||||||||  Avastin (bevacizumab) / Roche
    Drug Induced Interstitial Lung Disease and Pneumothorax After Treatment with Bevacizumab (Area F, Hall F (North Building, Exhibition Level), Moscone Center) -  Feb 19, 2022 - Abstract #ATS2022ATS_1001;    
    Clin Med Insights Circ Respir Pulm Med. 2020 Jun 15;14:1172.Kazuhiro Usui, Yuu Katou, Kaoru Furushima, Yoshiaki Tanaka, Chiharu Tanai, Teruo Ishihara Interstitial Lung Disease During Chemotherapy Combined with Oxaliplatin and/or Bevacizumab in Advanced Colorectal Cancer Patients Japanese Journal of Clinical Oncology, Volume 41, Issue 4, April 2011, Pages 498–502
  • ||||||||||  Vectibix (panitumumab) / Amgen
    Trial completion:  PARADIGM: Panitumumab and RAS, Diagnostically-useful Gene Mutation for mCRC (clinicaltrials.gov) -  Feb 18, 2022   
    P3,  N=823, Completed, 
    2020 Jun 15;14:1172.Kazuhiro Usui, Yuu Katou, Kaoru Furushima, Yoshiaki Tanaka, Chiharu Tanai, Teruo Ishihara Interstitial Lung Disease During Chemotherapy Combined with Oxaliplatin and/or Bevacizumab in Advanced Colorectal Cancer Patients Japanese Journal of Clinical Oncology, Volume 41, Issue 4, April 2011, Pages 498–502 Active, not recruiting --> Completed
  • ||||||||||  locnartecan (PEN-866) - Tarveda Therap, National Cancer Institute / Bethesda
    Trial completion date, Trial primary completion date:  PEN-866 in Patients With Advanced Solid Malignancies (clinicaltrials.gov) -  Feb 16, 2022   
    P1/2,  N=340, Recruiting, 
    cfDNA integrity index (ALU 247/115) % change rather than its absolute value is superior to CEA, CA19-9, cfDNA concentration and their % changes in early assessment of response to chemotherapy. Trial completion date: Jun 2022 --> Jun 2023 | Trial primary completion date: Dec 2021 --> Jan 2023
  • ||||||||||  Trial completion date, Trial primary completion date:  Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial (clinicaltrials.gov) -  Feb 16, 2022   
    P1,  N=40, Recruiting, 
    Trial completion date: Jun 2022 --> Jun 2023 | Trial primary completion date: Dec 2021 --> Jan 2023 Trial completion date: Feb 2025 --> Feb 2026 | Trial primary completion date: Feb 2022 --> Feb 2023
  • ||||||||||  Retrospective data, Journal:  Efficacy and safety of modified FOLFIRINOX as salvage therapy for patients with refractory advanced biliary tract cancer: a retrospective study. (Pubmed Central) -  Feb 15, 2022   
    Background Gemcitabine plus cisplatin is regarded as the standard first-line therapy for patients with advanced biliary tract cancer (BTC); however, no standard chemotherapy has yet been recommended after treatment failure...Patients were intravenously administrated with oxaliplatin (65 mg/m), leucovorin (400 mg/m), irinotecan (150 mg/m), and continuous infusion of fluorouracil (2400 mg/m) over 46 h...The most common grade 3/4 AE was neutropenia (n = 3, 20.0%), while there was no occurrence of febrile neutropenia. Conclusion Treatment with mFOLFIRINOX has promising efficacy and favorable tolerance as salvage therapy in patients with refractory advanced BCT.
  • ||||||||||  Udenyca (pegfilgrastim biosimilar) / Coherus Biosci
    Journal:  Conversion to biosimilar pegfilgrastim-cbqv enables budget-neutral access to FOLFIRINOX treatment for metastatic pancreatic cancer. (Pubmed Central) -  Feb 15, 2022   
    In a 2500-patient panel at 100% conversion, savings of US$6,907.41 per converted patient over 12 cycles of prophylaxis translate to US$17.3 million and could provide 72,273 additional FOLFIRINOX doses or 6023 full 6-month regimens. Conversion to biosimilar CIN/FN prophylaxis can generate significant cost-savings and provide budget-neutral expanded access to FOLFIRINOX treatment for patients with metastatic pancreatic cancer.
  • ||||||||||  varlitinib (ASLAN001) / ASLAN Pharma
    Trial completion, Enrollment change, Combination therapy, Metastases:  Varlitinib in Combination With mFOLFOX6 for Advanced or Metastatic Gastric Cancer (First Line) (clinicaltrials.gov) -  Feb 15, 2022   
    P2/3,  N=52, Completed, 
    FOLFIRINOX has a manageable safety profile in this population and should be considered in fit older adults with APC. Active, not recruiting --> Completed | N=400 --> 52
  • ||||||||||  tolinapant (ASTX660) / Otsuka
    Clinical, Journal:  Clinical Positioning of the IAP Antagonist Tolinapant (ASTX660) in Colorectal Cancer. (Pubmed Central) -  Feb 11, 2022   
    Further analyses revealed that caspase-8 knockout RIPK3-positive colorectal cancer models were sensitive to tolinapant-induced necroptosis, an effect that could be exploited in caspase-8-proficient models using the clinically relevant caspase inhibitor emricasan. Our study provides evidence for immediate clinical exploration of tolinapant in combination with FOLFOX in poor prognosis MSS colorectal cancer with elevated cIAP1/2 expression.
  • ||||||||||  cisplatin / Generic mfg.
    Journal:  Outcomes in patients receiving palliative chemotherapy for advanced biliary tract cancer. (Pubmed Central) -  Feb 11, 2022   
    This study therefore provides important real-world data on the established first- and second-line treatments with gemcitabine + cisplatin and FOLFOX, as well as on other chemotherapy regimens or later lines of chemotherapy. It further demonstrates that the use of FOLFIRINOX is associated with promising survival and that there is an association between various clinical parameters such as pre-therapeutic albumin, bilirubin or carbohydrate antigen 19-9 levels and survival.
  • ||||||||||  Jelmyto (mitomycin urothelial gel) / UroGen
    Enrollment change, Trial completion date, Trial primary completion date:  PIPAC for the Treatment of Peritoneal Carcinomatosis in Patients With Ovarian, Uterine, Appendiceal, Colorectal, or Gastric Cancer (clinicaltrials.gov) -  Feb 11, 2022   
    P1,  N=49, Recruiting, 
    It further demonstrates that the use of FOLFIRINOX is associated with promising survival and that there is an association between various clinical parameters such as pre-therapeutic albumin, bilirubin or carbohydrate antigen 19-9 levels and survival. N=16 --> 49 | Trial completion date: Mar 2022 --> Feb 2023 | Trial primary completion date: Mar 2022 --> Feb 2023
  • ||||||||||  oxaliplatin / Generic mfg.
    Journal, IO biomarker:  Exosomal miR-208b Related with Oxaliplatin Resistance Promotes Tregs expansion in Colorectal Cancer. (Pubmed Central) -  Feb 9, 2022   
    Furthermore, in vivo studies indicated that Tregs expansion mediated by cancer cell-secreted miR-208b resulted in tumor growth and oxaliplatin resistance. Our results demonstrate that tumor-secreted miR-208b promotes Tregs expansion by targeting PDCD4 and it may be related to decrease of oxaliplatin-based chemosensitivity in CRC.
  • ||||||||||  5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg.
    Clinical, Journal:  Prevotella contributes to individual response of FOLFOX in colon cancer. (Pubmed Central) -  Feb 8, 2022   
    In patients with metastatic pancreatic adenocarcinoma treated with FOLFIRINOX in first line, dose modifications at the onset of adverse effects and early use of granulocyte-colony stimulating factor seem to be associated with a better survival. No abstract available